Compounds > 4-(4-fluorophenoxy)benzaldehyde semicarbazone
Page last updated: 2024-11-11

4-(4-fluorophenoxy)benzaldehyde semicarbazone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-(4-fluorophenoxy)benzaldehyde semicarbazone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9816959
CHEMBL ID287833
CHEBI ID92156
MeSH IDM0306143

Synonyms (30)

Synonym
BRD-K08890269-001-01-5
NCGC00167807-01
4-(4-fluorophenoxy)benzaldehyde semicarbazone
(e)-2-(4-(4-fluorophenoxy)benzylidene)hydrazinecarboxamide
bdbm50141073
CHEMBL287833 ,
v-102862
2-(4-(4-fluorophenoxy)benzylidene)hydrazinecarboxamide
hydrazinecarboxamide, 2-[[4-(4-fluorophenoxy)phenyl]methylene]-
AKOS016004881
0kn11h90gf ,
2-((4-(4-fluorophenoxy)phenyl)methylene)hydrazinecarboxamide
unii-0kn11h90gf
hydrazinecarboxamide, 2-((4-(4-fluorophenoxy)phenyl)methylene)-
fphobal semicarbazone
[(e)-[4-(4-fluorophenoxy)phenyl]methyleneamino]urea
c14h12fn3o2
2-[[4-(4-fluorophenoxy)phenyl]methylene]hydrazinecarboxamide
HB1013
CHEBI:92156
J-011566
(e)-2-(4-(4-fluorophenoxy)benz-ylidene)hydrazinecarboxamide
A920653
[(e)-[4-(4-fluorophenoxy)phenyl]methylideneamino]urea
HMS3677N07
HMS3413N07
AMY36747
MS-23875
HY-108504
CS-0029016

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The method was used for the routine analysis of Co 102862 in mouse, rat, monkey and dog plasma and summary of the pharmacokinetic data are presented."( Development of a high-performance liquid chromatographic-tandem mass spectrometric method for the determination of pharmacokinetics of Co 102862 in mouse, rat, monkey and dog plasma.
Chien, B; Lam, GN; Ramu, K, 2000)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium channel protein type 4 subunit alphaHomo sapiens (human)Ki0.18000.18000.18000.1800AID205290
Sodium channel protein type 9 subunit alphaHomo sapiens (human)Ki0.36000.36000.43000.5000AID502843
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
sodium ion transportSodium channel protein type 4 subunit alphaHomo sapiens (human)
muscle contractionSodium channel protein type 4 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 4 subunit alphaHomo sapiens (human)
regulation of skeletal muscle contraction by action potentialSodium channel protein type 4 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 4 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 9 subunit alphaHomo sapiens (human)
inflammatory responseSodium channel protein type 9 subunit alphaHomo sapiens (human)
circadian rhythmSodium channel protein type 9 subunit alphaHomo sapiens (human)
response to toxic substanceSodium channel protein type 9 subunit alphaHomo sapiens (human)
post-embryonic developmentSodium channel protein type 9 subunit alphaHomo sapiens (human)
sensory perception of painSodium channel protein type 9 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 9 subunit alphaHomo sapiens (human)
behavioral response to painSodium channel protein type 9 subunit alphaHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of painSodium channel protein type 9 subunit alphaHomo sapiens (human)
detection of mechanical stimulus involved in sensory perceptionSodium channel protein type 9 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 9 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
voltage-gated sodium channel activitySodium channel protein type 4 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 4 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 9 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 9 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneSodium channel protein type 4 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 4 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 9 subunit alphaHomo sapiens (human)
axonSodium channel protein type 9 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 9 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID19689Partition coefficient (logP)1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.
AID244690Dissociation constant for binding to resting state of rat brain NaIIa (rNav1.2) -B2 cell line stably expressed in HEK293 Cells2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Phenoxyphenyl pyridines as novel state-dependent, high-potency sodium channel inhibitors.
AID112290Compound was tested for anticonvulsant activity after intraperitoneal injection into mice by using MES screen test after 1 hr1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.
AID121854Compound was tested for toxicity after intraperitoneal injection into mice by using neurotoxicity screen test after 1 hr1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.
AID226509Protection index = TD50/ED50 (MES)1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.
AID178169Compound was tested for anticonvulsant activity after Oral Administration into rat by using MES screen test after 2 hr1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.
AID249395Ratio between Kr to Ki2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Phenoxyphenyl pyridines as novel state-dependent, high-potency sodium channel inhibitors.
AID112298Compound was tested for anticonvulsant activity after intraperitoneal injection into mice by using scPTZ screen test after 1 hr1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.
AID170610Compound was tested for anticonvulsant activity after Oral Administration into Rats by using MES screen test after 0.5h,dose 50 mg/kg; number of rats out of four which were protected1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.
AID190106Compound was tested for toxicity after oral administration in rat by using neurotoxicity screen test after 0.25-24 hr1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.
AID109719Anticonvulsant activity after intraperitoneal injection into mice measured in a maximal electroshock scree (MES) screen1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.
AID205292Affinity for resting human SkM1 sodium channel expressed in HEK293 cells2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers.
AID232413Relative affinity for inactivated and resting human SkM1 expressed in HEK293 cells2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers.
AID170483Compound was tested for anticonvulsant activity after Oral Administration into Rats by using MES screen test after 0.25h,dose 50 mg/kg; number of rats out of four which were protected1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.
AID253081Inhibition of native TTX-S sodium currents in acutely dissociated rat dorsal root ganglion (DRG)2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Phenoxyphenyl pyridines as novel state-dependent, high-potency sodium channel inhibitors.
AID244602Dissociation constant for binding to inactivated state of rat brain NaIIa (rNav1.2) -B2 cell line stably expressed in HEK293 Cells2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Phenoxyphenyl pyridines as novel state-dependent, high-potency sodium channel inhibitors.
AID205290Affinity for inactive human SkM1 sodium channel expressed in HEK293 cells2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers.
AID253080Inhibition of native TTX-R sodium currents in acutely dissociated rat dorsal root ganglion (DRG)2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Phenoxyphenyl pyridines as novel state-dependent, high-potency sodium channel inhibitors.
AID167919Compound was tested for anticonvulsant activity after Oral Administration into Rats by using MES screen test after 4h,dose 50 mg/kg; number of rats out of four which were protected1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.
AID502843Binding affinity to human Nav1.72010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers.
AID109718Anticonvulsant activity after intraperitoneal injection into mice by using MES screen test after 0.5 hr1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.
AID170631Compound was tested for anticonvulsant activity after Oral Administration into Rats by using MES screen test after 2h,dose 50 mg/kg; number of rats out of four which were protected1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.
AID170621Compound was tested for anticonvulsant activity after Oral Administration into Rats by using MES screen test after 1h,dose 50 mg/kg; number of rats out of four which were protected1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (15.38)18.2507
2000's8 (61.54)29.6817
2010's1 (7.69)24.3611
2020's2 (15.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.09 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phenytoin
[no description available]		2.730imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
carbamazepine
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.		2.9340dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		1.9910branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
lamotrigine
[no description available]		2.71301,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic
cyclopentane
Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.		3.1310cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent
tetrodotoxin
Tetrodotoxin: An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order TETRAODONTIFORMES, which are eaten. The toxin causes paresthesia and paralysis through interference with neuromuscular conduction.. tetrodotoxin : A quinazoline alkaloid that is a marine toxin isolated from fish such as puffer fish. It has been shown to exhibit potential neutotoxicity due to its ability to block voltage-gated sodium channels.		2.0310azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid		animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker
ConditionIndicatedRelationship StrengthStudiesTrials
Absence Seizure
[description not available]		01.9910
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		01.9910
Ache
[description not available]		03.8640
Peripheral Nerve Diseases
[description not available]		03.6330
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		03.8640
Peripheral Nervous System Diseases
Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.		03.6330
Nerve Pain
[description not available]		02.0510
Neuralgia
Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.		02.0510
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Allodynia
[description not available]		02.0310
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		0210